P03 Long term denosumab treatment in osteoporosis - a case series

INTRODUCTION: Studies have shown that denosumab reduces fracture risk and increases bone mineral density and is associated with low adverse events over 10 years. We have reviewed 3 patients in our hospital who have been successfully treated with denosumab 20 injections. CASE DESCRIPTION: Clinical details of these patients are outlined in the table. DISCUSSION: All three patients have responded well to denosumab therapy with definite improvement of T scores and positive bone mineral density change compared to baseline, in both spine and hip regions. They have not experienced significant side effects related to treatment. The second patient was treated as possible fracture as the x-rays were not convincing of definitive fracture. Patient 3, despite having very low T scores and multiple fragility fractures in 2012, has not incurred further fractures following the commencement of denosumab. KEY LEARNING POINTS: Denosumab has shown satisfactory improvement in these patients without significant adverse effects, following completion of 10 years of therapy. This is in par with previous studies that demonstrated efficacy and safety profile of Denosumab.